Primo Medical Group
Primo Medical Group is an industry leader in the development, manufacture, and assembly of quality medical devices and precision machine components. Years of experience in the manufacturing industry along with unparalleled customer service enable the company to meet its customers’ needs and expectations now and into the future.
Primefocus Health
Simplifying Healthcare Recovery at Home for Healthier Patients. Primefocus Health is a spinout from LG Electronics building a digital health platform that enables healthcare providers to deliver a better, complete-care experience to patients as they transition from hospital to home. Read more about us here: https://primefocushealth.com | Primefocus Health is the first new venture unveiled by LG Electronics. At CES, Primefocus Health will demonstrate its new healthcare solution built for providers to support patients’ recovery at home with a remote management and healthcare delivery platform. Key areas of focus are rural health, obesity, and remote physical therapy.
Primax
Primax provides banks with payment processing services and an expansive array of value-added technology and solutions. Primax’s customizable solutions, including risk management, mobile and online card management, data and analytics, loyalty programs, marketing, strategic consulting, delinquency management and contact center services, help banks profitably grow their portfolios and deliver an unparalleled experience to their accountholders. With a longstanding commitment to service excellence, Primax has been designing and providing support services for banks throughout the U.S. and the Caribbean for over 40 years. For more information, visit primax.us
Pretika Corporation
Connected Wound Care Technology: Allowing Clinicians to monitor in Real Time the healing process of Acute and Chronic wounds with a non-invasive Multispectral, Hyperspectral and Digital Imaging Technology without having to remove the dressings, bandages, wraps, or casts for the early detection of complications before they become serious.
Prestige Biopharma Limited
Prestige Biopharma (PBP) is a Singapore-based biopharmaceutical company focusing on discovery, research, development and registration of biosimilars, first-in-class antibody drugs and vaccines, with the aim of finding cures and preventive medicines for devastating diseases, and to provide through our partners access to affordable quality biologics to the patients of the world. Prestige Biopharma strives to become a global innovator through the development of first-in-class antibody therapeutics including PBP1510 anti-PAUF mAb for pancreatic cancer (INN-ulenistamab) that obtained orphan designation from FDA, EMA and MFDS. Another 10 bispecific antibody projects based on PBP’s proprietary oncology therapeutic targets, PAUF and CTHRC1, are currently in development. Prestige Biopharma’s rich portfolio of biosimilars in various stages consist of the lead program, HD201, a trastuzumab biosimilar, currently under review by Health Canada and Korean MFDS, HD204, a bevacizumab biosimilarin Phase 3 of clinical development and planned to be filed in Q4/2023, PBP1502 an adalimumab biosimilar currently in phase I. Other biosimilars in the pipeline include aflibercept, eculizumab, ipilimumab, nivolumab, pembrolizumab, pertuzumab, and others. Prestige Biopharma’s area of capabilities also includes full value chain technological platform for drug discovery leading to expedited development, from drug discovery, non-clinical and clinical development, to regulatory registration and global commercialization together with our partners. Prestige Biopharma, together with Prestige Biologics, also expanded its business into development and manufacturing of vaccines at global scale vaccine center, starting with partnered commercial production of COVID-19 vaccines, and collaboration in developing next generation vaccines for potential future pandemics. Prestige Biopharma’s dedicated manufacturing facility, Prestige Biologics, is a biopharmaceutical CDEMO (Contract Development Engineering Manufacturing Organization) that provides complete solutions to the development and manufacturing requirements in drug discovery from early stage to product registration and commercialization. With its fully established antibody drug and vaccine manufacturing capabilities, Prestige Biologics offers CDEMO services in which customized engineering solutions are provided for manufacturing process in a customized manufacturing suite speed-built with its proprietary technology, ALITA Smart BioFactory™. Currently, a total production capacity of 154,000L with Full Single-Use System and ALITA Smart BioFactory™ is available for global clients. | PRESTIGE BIOPHARMA LTD (PBP) is a rapidly-expanding, biopharmaceutical company, with an Innovative Drug Development Platform from Discovery to CMC analysis to GMP Product Manufacturing. We are pioneers in pancreatic cancer, with novel antibody drugs and diagnostics targeting PAUF (biomarker for pancreatic cancer) under development. We also specialize in development and manufacturing of biosimilars. Located in Busan, Korea’s second largest city, the Innovative Discovery Center (IDC) stands as Prestige Biopharma’s global-scale R&D center, serving as the nucleus for pioneering novel drug development initiatives. Equipped with cutting-edge scientific infrastructure, IDC is dedicated to developing novel therapeutic antibodies to overcome unmet medical needs. Leveraging expertise and resources, we focus on first-in-class antibody drugs addressing life-threatening diseases and fostering innovation. To fulfill these roles, our scope covers from the initial stages of target identification, through the critical steps of the mechanism of action (MoA) studies, lead finding and optimization, to comprehensive preclinical studies, culminating in the IND (Investigational New Drug) filing. Additionally, we are dedicated to the in-house development of cell line development (CLD) technologies, focusing on engineering cell lines that can produce therapeutic proteins at high yields. Moreover, we develop bioanalytical analysis methods to ensure the integrity and performance of our biologics. This integrated approach ensures that the IDC contributes significantly to successful drug development. IDC aims to establish an open innovation platform by fostering synergy between science and technology, implementing a comprehensive innovative drug platform (‘Plug and Play’) and offering shared lab opportunities, allowing global academic institutions, enterprises, or entrepreneurs to assemble and collaborate for the development of pharmaceutical solutions. Prestige Biologics, our dedicated CDEMO, provides One-Stop Solutions for biomanufacturing from drug development to commercial manufacturing. We provide comprehensive support throughout the drug development lifecycle, including technical research, manufacturing process development, engineering, clinical production, commercial manufacturing, clinical support, and IND and BLA filings. Through this integrated approach, we deliver the most effective services to our customers in the rapidly evolving biopharmaceutical market. | Prestige Group has a comprehensive value chain platform, encompassing the entire drug discovery cycle, from R&D to manufacturing, clinical development, regulatory registration and commercialization, bringing innovative therapeutics to the market seamlessly and efficiently to address unmet medical needs. Prestige Biopharma Limited (PBP) is a Singapore-based biopharmaceutical company dedicated to the discovery, research, development and registration of biosimilars and first-in-class antibody drugs with a strong focus on oncology and immunology. Located in Busan, Korea, the Innovative Discovery Center (IDC) stands as PBP’s global-scale R&D center, fostering innovation, and driving the development of biologics including first-in-class antibody drugs and platform technologies aimed at addressing life-threatening diseases. Our scope spans the full range of activities, from early discovery and target identification to comprehensive preclinical studies, culminating in the Investigational New Drug (IND) filing for clinical trial initiation. Additionally, IDC has established a robust cell line development (CLD) system to engineer high-yield therapeutic protein-producing cell lines. PBP’s dedicated manufacturing facility, Prestige Biologics, is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides complete solutions to the development and manufacturing requirements in drug discovery from early stage to product registration and commercial supply. Currently, a total production capacity of 154,000L with Full Single-Use System is available for clients worldwide.
Premosys GmbH
PREMOSYS GmbH is a leading provider of high-precision optical measurement and sensor technology. Our innovative solutions ensure accuracy, efficiency, and quality assurance in medical, agricultural, and biotechnological applications. Our sensor systems are modular in design and can be used as standalone devices, OEM products, or integrated as in-line sensors, offering maximum flexibility and adaptability to suit your specific application (https://www.premosys.de/en/measurementsystems). With our business units Premosys Engineering and Premosys Automatization, we offer precision, reliability, and smart automation solutions tailored to your specific needs. Our expertise spans development and implementation, commissioning, and service, delivering innovative inspection and automation solutions designed to meet the unique requirements of your applications. Trust in our experience and competence to lead and execute your projects successfully (https://www.premosys.de/en/engineering). Solutions for Key Industries Medical & Biotechnological Applications • OPLYTIX mini spectrometers and multispectral sensor chips for simple quality control tasks up to precise spectrum analysis • Development of optical measurement systems for process analysis and monitoring • Tailored implementation of measurement devices into existing systems and infrastructures Agricultural Technology • Multispectral sensor systems for monitoring crop health and optimizing nutrient management • Optical measurement systems for precise application of herbicides and sustainable farming • Tailored inline measurement solutions for real-time process analysis and integration into existing agricultural systems With cutting-edge technology and customized solutions, PREMOSYS empowers industries to achieve excellence in quality control, research, and sustainable development. Visit our booth to discover how PREMOSYS can optimize your processes with innovative sensor and automation solutions!
Predictive AI
Predictive AI is a precision medicine deep-tech company developing the world’s first DNA-based Human Digital Twin AI platform. By integrating genomic, clinical, and real-world data, we enable personalized disease prediction, liquid biopsy diagnostics, and AI-powered medical decision support for preventive healthcare.
Precision Ocular Network
Precision Epigenomics
Precision Epigenomics® Inc. is an innovative molecular diagnostics company focused on revolutionizing early cancer detection through liquid biopsy testing. By analyzing the epigenome – the complex system that controls expression of DNA – we can detect hidden cancers through screening, study patients for the presence of any residual cancer following treatment, and follow survivors for surveillance of cancer recurrence. With a commitment to advancing the field of molecular diagnostics, we aim to create significant value in the rapidly growing oncology diagnostics market, and, above all, to improve the outcomes and lives of many patients affected by cancer. The Problem In 2025, more than 2 million new cancer cases are projected to be diagnosed in the United States–many of them at late stages. Screening protocols for some cancers such as breast or lung cancer have made some progress, but perform poorly due to patients now knowing which test to take and when, the financial and time commitment, discomfort, and low accuracy. Globally more than 20 Million new cases and 10 Million dying each year from cancer, this is unacceptable. The Solution Liquid biopsies present a minimally invasive sampling process (blood or other fluid collection from a patient) that have been gaining momentum as a validated diagnostic tool. Precision Epigenomics has developed and launched a novel blood-based testing protocol, EPISEEK, which identifies a unique set of DNA biomarkers that consistently change in human cancers, but remain stable in normal tissues. Our proprietary bioinformatics analysis can detect abnormal methylation signals present in more than 60 types of cancer. EPISEEK has demonstrated better accuracy compared to other liquid biopsy tests for detecting brain, pancreas, and lung cancer types, among others. Our qPCR platform is a lower cost structure than commonly used sequencing platforms, has faster turnaround times, is globally scalable, and can be applied to pleural fluid, cerebral spinal fluid, and other biospecimens as our product portfolio expands. With these technology advantages, with our CLIA lab-validated and available EPISEEK™ test, and with a focused pipeline of first-to-market tests for specific medical uses, Precision Epigenomics is positioned to save lives and flourish in the rapidly growing liquid biopsy market. Market Opportunity The U.S. market for early cancer detection is a fast-emerging, multi-billion-dollar opportunity, driven by demand for non-invasive sample collection, favorable regulatory trends, and payer support. As multi-cancer early detection (MCED) technologies gain traction screening asymptomatic and high-risk patients, the market is poised for rapid expansion and long-term disruption of traditional cancer diagnostics. Estimated market size for MCED screening: $74+B; CNS-Glioma detection: $1.1B; Malignant Pleural Effusion: $2.1B; Melanoma: $.5B; Head & Neck: $.5B. Commercialization Strategy With EPISEEK™ now optimized, validated, and orderable from our Tucson-based clinical laboratory, we are implementing our commercialization plans immediately for growth. We are focused on key partnerships that will drive volume: commercial labs, imaging collaborators, large concierge medicine practices, employee benefit programs, and high-risk patient groups. With sales and marketing staff now on board, we have launched targeted programs to build awareness, communicate our differentiation, and grow quickly. In the next two years, we will launch two new products that will be first to market in each category, offering physicians a less-invasive test to improve patient care for pulmonary and glioma patients. These products will be commercialized as broadly reimbursed tests, championed by key opinion leaders, supported by peer-reviewed publications and ongoing clinical data generation, and sold to practicing physicians through a highly specialized product sales force.
PrecisemAb Biotech Co., Ltd.
PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, can significantly reduce side effects caused by antibody drugs, making antibody therapy safe and effective. [Features of Core Technology (Antibody Lock)] ‧Higher masking ability and removal ability ‧Low immunogenicity ‧Prevention of anti-drug antibody binding ‧Prolonged serum half-life [Lead Product] PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1. [Partnering] Through the (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials. | PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. [Features of Antibody Lock] ★Medication safety with minimized adverse effects ★Elevating treatment efficacy for cancer cure ★Precision-designed for targeting various cancers [Partnering] PrecisemAb licenses Lock-antibodies for further clinical trials through: (1) Co-development of Lock-antibodies: [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β (2) Customized Antibody Lock Design Service: Including 4 steps to design your own Lock-antibody. | Company Overview Founded in October 2021, PrecisemAb Biotech was established by the late Professor Tian-Lu Cheng, former Vice President of Kaohsiung Medical University (KMU), as a KMU spin-off company. PrecisemAb focuses on applying the exclusively licensed Universal Antibody Lock Technology to develop next-generation precision antibody drugs with high specificity, low side effects, and enhanced therapeutic efficacy. Innovations & Advantages of the Universal Antibody Lock Platform The Universal Antibody Lock Technology integrates a Hinge + Linker structure that connects the VL/VH domains of an antibody. This unique design prevents antibodies from binding to healthy tissues until they reach the tumor microenvironment (TME). The Hinge-based lock, derived from human IgG1, serves as a masking mechanism, reducing unwanted interactions with normal tissues. The Linker, optimized through computational modeling, includes tumor-specific protease cleavage sites and spatial adjustment regions that ensure precise activation in the tumor microenvironment (TME). This mechanism enables antibodies to remain inactive in normal tissues and only activate when exposed to tumor-specific proteases, thereby minimizing off-target toxicity and enhancing therapeutic efficacy. By selectively triggering antibody activation at the tumor site, this technology significantly reduces side effects and improves treatment outcomes, ultimately enhancing patient quality of life. Compared to competing platforms, the Universal Antibody Lock Technology offers several key advantages. First, the human IgG1 hinge-based lock has low immunogenicity, reducing the risk of anti-drug antibody (ADA) formation and avoiding interference with drug efficacy. Second, the platform is highly versatile, allowing seamless integration into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies (BsAbs), which accelerates the development timeline for Lock-antibody drugs. Third, the linker design, incorporating tumor-specific protease cleavage sites and spatial adjustment regions, delivers the highest antibody activation rate globally in TME. The Universal Antibody Lock Technology has been adopted for industry collaboration. In May 2024, GlycoNex Biotech signed a non-exclusive licensing agreement with PrecisemAb, further demonstrating its applicability in antibody drug development. Drug Development (1) PrecisemAb’s lead drug, PSM101 (Lock-EGFR antibody), is designed for EGFR-expressing cancers, including head and neck cancer and colorectal cancer. The drug has successfully completed in vitro and in vivo efficacy and safety studies, cell line development, upstream process optimization (yield: 4.2 g/L), downstream process optimization, formulation research, and accelerated stability testing. PSM101 is planned for IND submission to the US FDA and TFDA in Q4 2026. (2) Additionally, PSM915 (Lock-TNF-α) has been evaluated in Biomedcode’s rheumatoid arthritis (RA) mouse model, demonstrating its ability to suppress RA disease progression and improve drug safety.